drugset / Trial / NCT01196546

Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)

NCT01196546

Phase 4 Completed 161 enrolled Novartis
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the efficacy and safety of combination therapy of vildagliptin/metformin in patients with T2DM inadequately controlled with metformin 1,000 mg/day.

Timeline

Start
2010-03
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 500 mg
Subject Metformin Small molecule 1000 mg
Subject Vildagliptin Other / unclassified 50 mg